<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>National Heart and Lung Institute</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/96476305-5352-492E-A324-03822CF64A59"><gtr:id>96476305-5352-492E-A324-03822CF64A59</gtr:id><gtr:firstName>Vania</gtr:firstName><gtr:surname>Braga</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FM026310%2F1"><gtr:id>D420A4DA-F68E-4CF8-BD65-4D321675CA0D</gtr:id><gtr:title>Newton001 Proof-of concept screen to counteract Bothrops toxins targeting tissue cohesion</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/M026310/1</gtr:grantReference><gtr:abstractText>In Brazil, the considerable human morbidity and mortality caused by accidents with poisoning animals pose high public health, economical and societal costs. Snakebite is a major occupational hazard, and rural subsistent farming communities are the main sufferers from this condition. Bothrops species are responsible for more than 20,000 accidents per year in Brazil, corresponding to 90% of all recorded snakebites. Bothrops spp. envenomation is characterized by prominent local tissue damage, including haemorrhage, necrosis and oedema as well as disturbance in the blood coagulation system. Since 1920's, immunotherapy by anti-venoms is the only efficacious treatment for snakebites accidents approved by WHO (World Health Organization). Yet, it has important limitations and side-effects, including inability to prevent local damage at the snakebite site and anaphylatic shock in some patients. Thus, there is an unmet clinical need to develop novel pharmacological therapies that can counteract snake venoms and/or be used as coadjuvant therapy with anti-venoms.

Understanding how the snake venom interfaces with cellular events important for tissue homeostasis is instrumental to inform novel therapies Yet, the molecular and cellular aspects of envenomation are poorly understood. This is in spite of extensive efforts from different labs in Brazil to characterise the biochemical properties of specific toxins and their in vivo consequences in animal models. The aim of the current Research Partnership from the Newton Fund/CONFAP is to (i) set up and optimise a screen to identify likely therapeutic candidates to facilitate cellular response to injury by Bothrops venom and (ii) develop novel techniques suitable to dissect mechanisms of snake envenomation.

Driven by unique strengths of the co-applicants in venom biochemistry and cellular signalling, this proposal will identify leads for drug development with important clinical implications for treatment of envenomation patients.</gtr:abstractText><gtr:technicalSummary>The proposed collaboration will increase our knowledge of mechanisms of action of toxins, which allows us to elucidate how the cell operates during envenomation. We will set up a screen to demonstrate the proof of principle that endogenous pathways are perturbed by Bothrops toxins and that inhibitors can be identified using this methodology. Within the time-frame of 12 months and focusing on cell-cell cohesion integrity phenotype, we propose to:

1. design and optimize a screen using primary cells (assays, readout, quantitative and statistical analysis);
2. identify which purified fractions of Bothrops venom targets cell cohesion;
3. validate results with inhibitors and specific identified targets; 
4. provide extensive technical and conceptual training in screen, cell biology and signalling.</gtr:technicalSummary><gtr:potentialImpactText>N/A</gtr:potentialImpactText><gtr:fund><gtr:end>2016-12-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-02-14</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>40051</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>113642</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pathfinder Award</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>201054/Z/16/Z</gtr:fundingRef><gtr:id>DA5B917F-0DA5-4913-B6CE-D3A8EA575723</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A background patent has been jointly filed between the Federal University of Minas Gerais (Brazil) and Imperial Innovations. This patent covers the assay technology which will be enable the screening proposed under this project. It claims a method to test the neutralizing potency of anti-Bothropic serum in vitro based on cell cultures. More specifically the method consists of the determination of ED50 (Effective Dose, 50%) in cells from the snake B. jararaca previously neutralized by anti-bothropic sera. The patent enables newly produced anti-sera in horses to be tested in order to determine their neutralizing potency of those anti-venoms and select for future use for the treatment of bite accidents by snakes of the genus Bothrops.</gtr:description><gtr:id>E53E5541-6054-4A8F-9288-E9F0F254CB8F</gtr:id><gtr:impact>It is possible that additional method of use IP may arise under this proposal and Imperial Innovations, with UFMG, will work towards assessing and filing patents on such novel IP.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>BR1020150264437</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>&amp;quot;In vitro methods for the determination of anti-venom potency: kit and its use&amp;quot;</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Optimized a methodology for biochemical an cell biology analysis of venom perturbations leading to cell death</gtr:description><gtr:id>88C77394-BA64-4EB4-B1BD-6B867F797AD8</gtr:id><gtr:impact>this methodology will bring about important mechanisms on how snake toxin injure cellular processes.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>in vitro system to study envenomation</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">MR/M026310/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>6393C0B5-F394-4AB6-9626-AD6D94C7BCB5</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Injuries and Accidents</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes><gtr:rcukProgramme><gtr:id>C11BDEA9-7D9D-4728-B6A9-31032921B328</gtr:id><gtr:text>Newton</gtr:text></gtr:rcukProgramme></gtr:rcukProgrammes></gtr:project></gtr:projectComposition></gtr:projectOverview>